ZYDUS LIFESCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 951.5 INR | -0.85% |
|
+0.64% | +37.97% |
| Apr. 22 | Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment | MT |
| Apr. 22 | Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US | MT |
| Sales 2024 * | 193B 2.31B | Sales 2025 * | 210B 2.52B | Capitalization | 966B 11.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 35.72B 429M | Net income 2025 * | 37.31B 448M | EV / Sales 2024 * | 4.94 x |
| Net cash position 2024 * | 14.67B 176M | Net cash position 2025 * | 35.75B 429M | EV / Sales 2025 * | 4.42 x |
| P/E ratio 2024 * |
26.8
x | P/E ratio 2025 * |
25.7
x | Employees | 23,026 |
| Yield 2024 * |
0.6% | Yield 2025 * |
0.61% | Free-Float | 24.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zydus Lifesciences Limited
More recommendations
More press releases
| 1 day | -0.92% | ||
| 1 week | +0.64% | ||
| Current month | -5.60% | ||
| 1 month | -6.50% | ||
| 3 months | +30.41% | ||
| 6 months | +66.72% | ||
| Current year | +37.97% |
1 week
913.20
968.05
1 month
913.201 031.70
Current year
686.001 031.70
1 year
484.951 031.70
3 years
319.001 031.70
5 years
202.001 031.70
10 years
174.421 031.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 97-07-31 | |
| Director of Finance/CFO | - | - | |
| Chairman | 71 | 95-05-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 18-12-05 | |
| Chairman | 71 | 95-05-14 | |
| Director/Board Member | 69 | 97-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 6 M€ | +6.07% | - | |
| 0.01% | 117 M€ | -0.72% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 951.5 | -0.85% | 399 702 |
| 24-04-22 | 959.7 | +4.07% | 1,739,090 |
| 24-04-19 | 922.2 | -1.58% | 1,482,222 |
| 24-04-18 | 937 | -0.83% | 1,376,748 |
| 24-04-16 | 944.8 | +1.04% | 2,235,559 |
Delayed Quote NSE India S.E., April 23, 2024 at 02:21 am EDT
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
959.7
INR
Average target price
838.5
INR
Spread / Average Target
-12.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.97% | 11.58B | |
| +20.33% | 44.31B | |
| +19.87% | 22.17B | |
| +14.63% | 14.62B | |
| +9.34% | 13.12B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B | |
| -1.14% | 4.27B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
